K. Hu

发表

Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial.

S. Melmed, J. Schopohl, A. Colao, 2010, The Journal of clinical endocrinology and metabolism.

Effect of verapamil on the pharmacokinetics of pasireotide in healthy volunteers

A. P. Tripathi, V. Passos, K. Hu, 2014, Journal of clinical pharmacology.

An Open-Label Dose-Escalation Study of Once-Daily and Twice-Daily Pasireotide in Healthy Volunteers: Safety, Tolerability, and Effects on Glucose, Insulin, and Glucagon Levels

M. Shenouda, K. Hu, Dalal Nesheiwat, 2014, American journal of therapeutics.

Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study.

G. Golor, K. Hu, Astrid Breitschaft, 2014, Diabetes research and clinical practice.

Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: A randomized, multicenter, open‐label, phase I study

J. Schopohl, J. Bollerslev, A. Arafat, 2014, Journal of clinical pharmacology.

Assessment of the absorption, metabolism and excretion of [14C]pasireotide in healthy volunteers using accelerator mass spectrometry

T. Lin, J. Flarakos, J. Mangold, 2013, Cancer Chemotherapy and Pharmacology.

Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study

E. Wolin, V. Giannone, K. Hu, 2013, Cancer Chemotherapy and Pharmacology.

Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I study

C. Beglinger, P. Mohideen, K. Hu, 2012, Endocrine.

Effect of Hepatic Impairment on the Pharmacokinetics of Pasireotide (SOM230): Results From a Multicenter Phase I Study

Y. Horsmans, D. Heuman, K. Hu, 2012, Journal of clinical pharmacology.

A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers

G. Golor, A. Buchelt, K. Hu, 2012, Drug design, development and therapy.

Pasireotide (SOM230), a Novel Multireceptor‐Targeted Somatostatin Analogue, Is Well Tolerated When Administered as a Continuous 7‐Day Subcutaneous Infusion in Healthy Male Volunteers

K. Mann, Yilong Zhang, S. Petersenn, 2012, Journal of clinical pharmacology.

Safety, tolerability, and pharmacokinetics of a single dose of pasireotide long-acting release in healthy volunteers: a single-center Phase I study.

J. Hasskarl, K. Hu, Yanfeng Wang, 2012, European journal of endocrinology.

Utility of Exposure‐Response Analysis in Regulatory Decision on the Selection of Starting Dose of Pasireotide for Cushing Disease

J. Nedelman, N. Mehrotra, Jingyu Yu, 2016, Journal of clinical pharmacology.

Tolerability and dose proportional pharmacokinetics of pasireotide administered as a single dose or two divided doses in healthy male volunteers: a single-center, open-label, ascending-dose study.

K. Mann, Yilong Zhang, S. Petersenn, 2012, Clinical therapeutics.

Pasireotide ( SOM 230 ) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR : results from a phase II study

L. Kvols, B. Wiedenmann, R. Arnold, 2012 .

patients with advanced neuroendocrine tumors refractory or resistant to

L. Kvols, B. Wiedenmann, R. Arnold, 2012 .

Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study.

L. Kvols, B. Wiedenmann, R. Arnold, 2012, Endocrine-related cancer.

Phase I dose-escalation study of long-acting pasireotide in patients with neuroendocrine tumors

James C Yao, A. Mita, M. Kundu, 2017, OncoTargets and therapy.

Long-term efficacy and safety of subcutaneous pasireotide in acromegaly

S. Melmed, J. Schopohl, P. Caron, 2018 .

Pharmacokinetics and safety of subcutaneous pasireotide and intramuscular pasireotide long-acting release in Chinese male healthy volunteers: a phase I, single-center, open-label, randomized study.

Xia Chen, Ji Jiang, P. Hu, 2014, Clinical therapeutics.

Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.

Y. Wang, A. Tabarin, J. Bertherat, 2009, The Journal of clinical endocrinology and metabolism.

Population Pharmacokinetics of Subcutaneous Pasireotide in Healthy Volunteers and Cushing’s Disease Patients

J. Nedelman, K. Hu, I. Paule, 2018, Clinical Pharmacokinetics.

Extended treatment of Cushing’s disease with pasireotide: results from a 2-year, Phase II study

J. Bertherat, M. Fleseriu, J. Schopohl, 2013, Pituitary.

An evaluation of the efficacy and safety of thrombolysis in patients with wake-up stroke using the combination of inflammatory factors Interleukin-6 and C-reactive protein with multi-mode magnetic resonance imaging

Qiwu Xu, Hao Wang, K. Hu, 2022, Clinical Neurology and Neurosurgery.

Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study

S. Melmed, J. Schopohl, P. Caron, 2013, Pituitary.

Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study

S. Melmed, J. Schopohl, P. Caron, 2013, Pituitary.

Effects of subcutaneous pasireotide on cardiac repolarization in healthy volunteers: A single-center, phase I, randomized, four-way crossover study

P. Jordaan, K. Hu, Astrid Breitschaft, 2013, Journal of clinical pharmacology.

Safety and efficacy assessment of allogeneic human dental pulp stem cells to treat patients with severe COVID-19: structured summary of a study protocol for a randomized controlled trial (Phase I / II)

Chu-Tse Wu, Gangqiao Zhou, Zun-en Xia, 2020, Trials.

Therapeutic effect and rebound evaluation of dapagliflozin on glycated hemoglobin (HbA1c) in type 1 diabetes mellitus patients

K. Hu, Xiao Chen, Sumei He, 2023, Frontiers in Pharmacology.

An open-label randomized controlled trial of leflunomide in patients with acute SARS-CoV-2 omicron variant infection

K. Hu, Yixuan Wang, Zhou Pan, 2023, Frontiers in medicine.